Immune therapy: a new therapy for acute myeloid leukemia
Author:
Publisher
Ovid Technologies (Wolters Kluwer Health)
Subject
Hematology
Reference76 articles.
1. Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL.;Tam;Blood,2019
2. Zanubrutinib (BGB-3111) plus obinutuzumab in patients with chronic lymphocytic leukemia and follicular lymphoma.;Tam;Blood Adv,2020
3. Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial.;Voorhees;Blood,2020
4. Daratumumab plus lenalidomide and dexamethasone for untreated myeloma.;Facon;N Engl J Med,2019
5. CLEC12A and CD33 coexpression as a preferential target for pediatric AML combinatorial immunotherapy.;Willier;Blood,2021
Cited by 5 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. High percentage of bone marrow CD8+ tissue-resident-like memory T cells predicts inferior survival in patients with acute myeloid leukemia;Blood Science;2024-06-07
2. Cysteine-binding adjuvant enhances survival and promotes immune function in a murine model of acute myeloid leukemia;Blood Advances;2024-03-29
3. Lymphocyte-activation gene 3 (LAG-3) as a promising immune checkpoint in cancer immunotherapy: From biology to the clinic;Pathology - Research and Practice;2024-02
4. Iron overload promotes the progression of MLL-AF9 induced acute myeloid leukemia by upregulation of FOS;Cancer Letters;2024-01
5. Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy;Journal of Hematology & Oncology;2023-09-05
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3